Related Experiment Video
Updated: Jun 23, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor
1Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California 94305, USA. nshulman@stanford.edu
Current Opinion in HIV and AIDS
|April 18, 2009
Summary
Nucleoside and non-nucleoside reverse transcriptase inhibitor combinations are effective HIV-1 treatments due to synergistic interactions. These drug combinations demonstrate potency and durability in clinical practice.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Antiretroviral therapy is crucial for managing HIV-1 infection.
- Fixed-dose combinations of nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used globally.
- The efficacy of these combined regimens is well-established for initial HIV-1 treatment.
Purpose of the Study:
- To review the synergistic interactions between NRTIs and NNRTIs.
- To explore the mechanisms underlying drug resistance in HIV-1 treatment.
- To understand the combined effects of NRTI and NNRTI resistance pathways.
Main Methods:
- Literature review of existing studies on NRTI and NNRTI interactions.
- Analysis of mechanisms of synergistic inhibition of HIV-1 reverse transcriptase.
- Examination of drug resistance pathways and their interplay.
Main Results:
- Synergistic effects are observed in the mechanisms of drug resistance.
- Interactions between NRTI and NNRTI resistance are multifaceted.
- This review consolidates current knowledge on these complex interactions.
Conclusions:
- Synergistic interactions are key to the effectiveness of NRTI/NNRTI combinations.
- These interactions contribute to the potency and long-term durability of the treatment regimens.
- Understanding these synergistic effects is vital for optimizing HIV-1 therapy.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...